At the molecular level, it has been shown that STC2 can modulate multiple signaling pathways, such as PI3K/AKT, ERK1/2, in tumor cells and osteoblast (Zhou et al., 2016; Yang et al., 2017). This evidence concerns the gene MAPK3 and neoplasm.